Shree Ganesh Bio-Tech (India) Limited has updated its corporate website address, notifying all listed exchanges of the change. The company’s new digital portal is now live at www.shreeganeshbiotech.bar .

Corporate Action Details

The firm issued a communication on September 1, 2026, to the Listing Departments of BSE Limited, The Calcutta Stock Exchange Ltd, and Metropolitan Stock Exchange of India Limited. The notice requests that these exchanges update their records to reflect the new web address and remove references to the previous site.

Shree Ganesh Bio-Tech directed its Wholesale Director, Aman Patel, to sign off on the filing. The document serves as an informational update for regulatory compliance and investor record-keeping purposes.

Key Information

• New Website: www.shreeganeshbiotech.bar
• Date of Notice: September 1, 2026
• Regulatory Recipients: BSE, CSE, MSEI

Shree Ganesh Biotech reported a standalone net loss of ₹57.32 lakh for the first quarter of FY27, marking a significant reversal from the net profit of ₹32.70 lakh recorded in the corresponding quarter of the previous year. The deterioration in profitability was driven by a sharp increase in cost of materials consumed, which outpaced a modest rise in revenue from operations.

The Board of Directors approved the unaudited financial results on August 4, 2026, pursuant to Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors Bipin & Co. conducted a limited review of the financial statements in accordance with Standard on Review Engagements (SRE) 2410.

Financial Performance

Revenue from operations increased to ₹142.99 lakh in Q1FY27, up from ₹138.36 lakh in Q1FY26. However, this growth was insufficient to offset rising expenses. Total expenses surged to ₹232.32 lakh from ₹147.19 lakh in the prior year period. The primary driver of this cost inflation was the cost of materials consumed, which jumped to ₹186.67 lakh from ₹111.97 lakh, indicating margin pressure in the core business operations.

Other income declined to ₹32.01 lakh from ₹41.53 lakh, further contributing to the bottom-line pressure. Employee benefit expenses also saw a notable rise, increasing to ₹5.85 lakh from ₹1.43 lakh year-on-year.

What the Numbers Show

The divergence between revenue growth and expense expansion highlights a critical operational challenge for Shree Ganesh Biotech. While top-line sales grew by approximately 3%, the cost of goods sold expanded by nearly 67%. This suggests that input cost inflation or pricing pressures have significantly eroded operating margins, turning a previously profitable quarter into a substantial loss. The company’s ability to manage material costs will be key to restoring profitability in subsequent quarters.